A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
VivoSim Labs, INC. operates in the Biological Products, (No Diagnostic Substances) industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 140K | - | - | - | - | 0 |
| Net Income | -2.0M | -2.5M | -15M | -17M | -11M | -17M |
| EPS | $0.51 | $-1.70 | $-19.20 | $-23.76 | $-15.84 | $-29.28 |
| Free Cash Flow | 0 | -9.5M | -15M | -13M | -8.9M | -14M |
| ROIC | -2478.3% | -23.7% | -331.0% | -91.4% | -37.9% | - |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.40 | 0.76 | 0.33 | 0.10 | - |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -12M | -13M | -15M | -18M | -11M | -17M |
| Operating Margin | -8694.3% | - | - | - | - | - |
| ROE | -28.1% | -35.3% | -155.0% | -112.6% | -37.9% | - |
| Shares Outstanding | 3M | 1M | 1M | 1M | 1M | 1M |
VivoSim Labs, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
VivoSim Labs, INC. (VIVS) has a 5-year average return on invested capital (ROIC) of -51.0%. This is below average and may indicate limited pricing power.
VivoSim Labs, INC. (VIVS) has a market capitalization of $4M. It is classified as a small-cap stock.
VivoSim Labs, INC. (VIVS) does not currently pay a regular dividend.
VivoSim Labs, INC. (VIVS) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
VivoSim Labs, INC. (VIVS) generated $-9 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
VivoSim Labs, INC. (VIVS) has a debt-to-equity ratio of 0.40. This indicates a conservatively financed balance sheet.
VivoSim Labs, INC. (VIVS) reported earnings per share (EPS) of $-1.70 in its most recent fiscal year.
VivoSim Labs, INC. (VIVS) has a return on equity (ROE) of -35.3%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 14 years of financial data for VivoSim Labs, INC. (VIVS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
VivoSim Labs, INC. (VIVS) has a book value per share of $7.17, based on its most recent annual SEC filing.